Community Health’s 10 Hospital Divestitures Generate $1.2 Billion and Cut Debt
Key Facts
Community Health Systems exited 10 hospitals during 2026 through 9 sale transactions and one lease transfer, according to Becker’s Hospital Review coverage published on October 29. In its quarterly report, the company detailed the exit of 4 hospitals in Arkansas, 3 in Pennsylvania and one in Alabama during the nine months ended September 30. It also sold its 80% stake in a Tennessee hospital during the same period. Net proceeds from the divestitures totaled about $1.2 billion, while the hospitals involved generated approximately $1.6 billion in annual operating revenue in 2025. The transactions put the reduction of the hospital portfolio at the center of the company’s moves, alongside weaker quarterly results and a revised annual outlook.
Operating revenue was $2.757 billion in the third quarter of 2026, down 10.7% from $3.087 billion in the same quarter of 2025, according to the earnings release filed with the U.S. Securities and Exchange Commission. Revenue at same-hospital facilities, however, rose 3.8%, a measure that excludes the effect of portfolio changes. The gap between the two figures reflects the impact of divestitures on total revenue, as well as the performance of facilities that remained in the portfolio. The chief executive said patient volume and cash flow trends improved sequentially during the quarter. He added that payer mix and acuity did not develop as management expected, weighing on results and the outlook for the rest of the year.
The company moved from net income attributable to shareholders of $130 million, or $0.96 per diluted share, in the third quarter of 2025 to a loss of $86 million, or $0.63 per share, in the third quarter of 2026. Adjusted earnings before interest, taxes, depreciation and amortization also fell to $280 million from $376 million a year earlier. The company attributed the decline in this measure to divestitures, changes in payer mix, lower non-patient revenue, physician specialty fees and supplemental compensation program expenses. Non-patient revenue in the comparison period had benefited from a $28 million legal settlement. The company said higher patient volumes and reimbursement rates partly offset these pressures.
In the nine months ended September 30, adjusted admissions fell 11.5% and adjusted patient admissions declined 11.4% compared with the same period in 2025. On a same-hospital basis, admissions rose 0.7% and adjusted admissions increased 1.9%, showing how activity trends differed when the effect of divestitures was excluded. In the same period, the company posted net income of $28 million, compared with $516 million a year earlier. The loss attributable to the company’s shareholders was $74 million, versus income of $399 million in the year-earlier period. The company attributed the decline in adjusted earnings over the nine months mainly to divestitures, an unfavorable payer mix and higher physician specialty fees, partly offset by higher reimbursement rates and improvement in some cost items.
The chief executive said actions taken by the company during the year are expected to generate future annual savings of more than $100 million, with additional opportunities still under review. Those actions include restructuring some departments, making use of enterprise resource planning systems and technology, and changes to service and procurement contracts. The executive described the future impact of the measures implemented up to that point as being in the range of $100 million. The announced savings come as the company lowered its financial outlook for 2026. The expected annual revenue range is now $11.3 billion to $11.5 billion, and the adjusted earnings range is $1.225 billion to $1.275 billion, with the midpoint of adjusted earnings lowered by 6.5%.
Management also cut its 2026 operating cash flow forecast to a range of $100 million to $300 million. It said a weaker payer mix and soft demand for elective commercial procedures affected its outlook for the rest of the year. The company, meanwhile, said its debt had fallen by $810 million since the start of the year and its next major maturity is in 2029. The debt reduction followed divestiture proceeds that approached $1.2 billion through September 30. The executive said the company saw sequential improvement in cash flow during the third quarter, but noted that payer mix and acuity performance fell short of management’s expectations.
In a separate filing, the company said it had accepted grants totaling about $27 million under the first-year funding of the Rural Health Transformation Program. The grants were allocated primarily to capital expenditures and software upgrades, and the company expects to receive the proceeds and fund related expenses intermittently through September 30, 2027. The federal program totals $50 billion over five years, with $10 billion available in each federal fiscal year from 2026 to 2030. The grants accepted by the company represent a share of the first-year funding, while its announced operating outlook reflects lower revenue and earnings, as well as pressure from payer mix and demand. The revised 2026 outlook, including the operating cash flow range, remains the nearest-term framework for tracking the impact of these factors on the company’s results.